Shares of Jazz Pharmaceuticals (JAZZ) have gained 8.9% over the past four weeks to close the last trading session at $127.74, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $175.83 indicates a potential upside of 37.7%.The average comprises 18 short-term price targets ranging from a low of $113 to a high of $230, with a standard deviation of $33.34. While the lowest estimate in ...

Have you assessed how the international operations of Jazz Pharmaceuticals (JAZZ) performed in the quarter ended September 2024? For this drugmaker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For inv ...

Jazz Pharmaceuticals (JAZZ) reported third-quarter 2024 adjusted earnings of $6.61 per share, which beat the Zacks Consensus Estimate of $5.47. Earnings rose 37% year over year.Total revenues rose 9% year over year to $1.05 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of $1.04 billion.Shares of Jazz were up 2% in yesterday’s after-market trading session, likely due to the better-than-expected earnings.The stock fell 9.3% year to date compared ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Market LLC Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 or ☐ Transition report pursuant to Sect ...

For the quarter ended September 2024, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.05 billion, up 8.5% over the same period last year. EPS came in at $6.61, compared to $4.84 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.04 billion, representing a surprise of +1.75%. The company delivered an EPS surprise of +20.84%, with the consensus EPS estimate being $5.47.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...

Jazz Pharmaceuticals plc. (NASDAQ:JAZZ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Andrea Flynn - Vice President and Head-Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renée Galá - President and Chief Operating Officer Rob Iannone - Executive Vice President and Global Head-R&D Phil Johnson - Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Jason Gerberry - Bank of America Marc Goodman - Le ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.61 per share, beating the Zacks Consensus Estimate of $5.47 per share. This compares to earnings of $4.84 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.84%. A quarter ago, it was expected that this drugmaker would post earnings of $4.68 per share when it actually produced earnings of $5.30, delivering a surprise of 13.25%.Over the last four quarters, the c ...

Exhibit 99.1 Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results – 14% year-over-year revenue increase from combined key growth drivers: Xywav , Epidiolex and Rylaze – – 2024 total revenue guidance affirmed at $4.0 to $4.1 billion – – Zanidatamab 2L BTC PDUFA date of November 29, 2024 – – Plan to submit sNDA for Zepzelca in 1L ES-SCLC in 1H25 – ® ® ® ® DUBLIN, November 6, 2024 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and updat ...

– 14% year-over-year revenue increase from combined key growth drivers:Xywav®, Epidiolex® and Rylaze® –– 2024 total revenue guidance affirmed at $4.0 to $4.1 billion –– Zanidatamab 2L BTC PDUFA date of November 29, 2024 –– Plan to submit sNDA for Zepzelca® in 1L ES-SCLC in 1H25 –DUBLIN, Nov. 6, 2024  /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and updated guidance for 2024."Jazz once again delivered record revenues of more than $1.0 ...

Celebrate in style with an unparalleled evening of dining, dancing and music in Naples' premiere luxury setting.NAPLES, Fla., Nov. 4, 2024 /PRNewswire/ -- This New Year's Eve, step into the epitome of elegance at The Ritz-Carlton, Naples where the resort's inaugural "NYE Black-Tie Gala" invites guests to experience an unforgettable celebration. Marking a premier addition to The Ritz-Carlton, Naples' distinguished lineup of events, this exclusive gala features a lavish five-course champagne dinner, live perf ...